Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 43Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1

Interventions

Gemcitabine 5Cisplatin 4enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1rucaparib 1pembrolizumab 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiation 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1Interleukin-7 1Immunoglobulin G 1Icrucumab 1IMC-18F1 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ureteral Neoplasms × eribulin × Clear all
NCT02178241 2019-12-16

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 9 charts

Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡